DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Perifosine is an investigational drug.
There have been 43 clinical trials for Perifosine. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Multiple Myeloma, Neoplasms, Plasma Cell, and Leukemia. The leading clinical trial sponsors are AEterna Zentaris, National Cancer Institute (NCI), and Dana-Farber Cancer Institute.
There are eight hundred and fifty-eight US patents protecting this investigational drug and eight international patents.
Recent Clinical Trials for Perifosine
|Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas||AEterna Zentaris||Phase 2|
|Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas||Pfizer||Phase 2|
|Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas||Andrew Lassman||Phase 2|
Top disease conditions for Perifosine
Top clinical trial sponsors for Perifosine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Perifosine||Start Trial||Compounds and their methods of use||Agios Pharmaceuticals, Inc. (Cambridge, MA)||Start Trial|
|Perifosine||Start Trial||Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers||IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)||Start Trial|
|Perifosine||Start Trial||Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity||The University of North Carolina at Chapel Hill (Chapel Hill, NC)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|